RT @AurelieRheumo: KEEPsAKE 2: Risankizumab RCT in Bio-IR or csDMARD-IR active PsA. Primary endpoint ACR20 W24 met with
Tweet Content
KEEPsAKE 2: Risankizumab RCT in Bio-IR or csDMARD-IR active PsA. Primary endpoint ACR20 W24 met with 51.3% vs 26.5% in PBO group (P < .001) and ACR50 26.3% vs 9.3%. No particular safety signal.
#OP0228 @Rheumnow #EULAR2021 https://t.co/HZv8qoc4sz
Show on Archive Page
On
Display in Search Results
On
PDQ
Off